About this event

  • Date and time Mon 4 Mar 2024 from 2:00pm to 4:00pm
  • Location Online
  • Organised by Radiology

With new treatments for Alzheimer’s disease on the horizon, this webinar offers an update on the current state of play of disease-modifying drugs in Alzheimer’s disease and on how imaging can impact the patient pathway.  

The potential role of Amyloid and Tau PET in the immunotherapy treatment pathway will be discussed as will the characteristics and impact of Amyloid Related Imaging Abnormalities (ARIA) seen on MRI. 

By attending, you will:

  • Understand the potential indications for novel disease-modifying drugs in Alzheimer’s disease and their potential risks and benefits 

  • Understand how PET could be used in the immunotherapy treatment pathway for Alzheimer’s Disease. 

  • Gain an understanding of the common imaging characteristics of amyloid-related Imaging Abnormalities (ARIA) on MRI. 

This webinar is available for on-demand viewing. The webinar recording will be available for registered event participants up to 60 days after the live webinar broadcast via Zoom. The link will be sent 24 hours after the webinar takes place.

Follow us on: 



Standard pricing available until 04 March 2024.


RSM Fellow RSM Associate RSM Retired Fellow RSM Trainee RSM Student
£24.00 £18.00 £18.00 £18.00 £12.00

Non - Member

AHP / Nurse / Midwife Consultant / GP / SAS Doctors Trainee Student
£33.00 £33.00 £33.00 £22.00

Key speakers

Dr Frederik Barkhof

Prof Frederik Barkhof

Consultant in Neuroradiology, University College London Queen Square Institute

Speaker's biography

Frederik Barkhof received his MD from VU University, Amsterdam (NL) in 1988 and defended his PhD thesis in 1992, for which he received the Philips Prize for Radiology (1992) and the Lucien Appel Prize for Neuroradiology (1994). Since 2001 he serves as a full Professor in Neuroradiology at the department of Radiology & Nuclear Medicine at VUmc. In 2015 he was appointed as full Professor of Neuroradiology at institutes of Biomedical Engineering and Neurology at UCL in London (UK) to translate novel imaging techniques. In 2018 he received the John Dystel Prize by the AAN and NMSS for his unique contributions to MS research. In 2019, he became a senior fellow of the ISMRM and in 2021 he received their Gold Medal.

Prof. Barkhof was the chairman of the Dutch Society of Neuroradiology and the MAGNIMS study group for many years. He is leading the Queen Square MS Centre Trial Unit, involved in analysis of multicenter drug trials. He serves on the Editorial boards of Radiology, Multiple Sclerosis Journal, Neuroradiology and Neurology. He is a fellow of the Royal College of Radiology.

His research interests focus on white matter disease, dementia, and glioma. He (co)authored >1300 papers referenced in PubMed, has an H-factor of 167 (Google Scholar) and is listed among 3000 most influential scientists world-wide by Thompson-Reuters. He is the author of the books “Neuroimaging in Dementia”, “Clinical applications of functional brain MRI” and “Clinical Neuroradiology – the ESNR textbook” with >250k chapter downloads.

Cumulatively, he has received >25 million euro of grant money from various national and international funding agencies and performed contract research for all major pharmaceutical companies with cumulative contract value of > 15 million euro. More than 70 PhD students graduated under his supervision and 4 of them have subsequently attained a full professorship.

Dr Bob Barber

Consultant Old Age Psychiatrist, Cumbria, Northumberland, Tyne and Wear NHS Foundation Trust

Speaker's biography

Prof Frederik Barkhof is a consultant in neuroradiology at University College London. His research interests focus on MRI in white matter disease, ageing & dementia and glioma and is an expert in amyloid related imaging abnormalities (ARIA). He is listed among the 3000 most influential scientists world-wide by Thompson-Reuters.

Dr Zarni Win

Consultant Radiology and Nuclear Medicine, Imperial College London

Speaker's biography

Dr Zarni Win is a dual accredited consultant in radiology and Nuclear Medicine at Imperial College London. He has a special interest in PET imaging in dementia and is an expert in Amyloid brain PET imaging.


View the programme 04 March 2024

Welcome and introduction

Chair: Dr George Petrides, Radiology Consultant, Newcastle Upon Tyne Hospitals 

NHS England update on disease modifying drugs in Alzheimer's disease

Ann Jarvis, Programme Director (Clinical Strategy),  NHS England 

Novel treatments in Alzheimer’s disease

Dr Bob Barber, Consultant in old age psychiatry and honorary senior lecturer Newcastle University          

Role of PET imaging with disease modifying drugs for Alzheimer’s disease

Dr Zarni Win, Consultant in Radiology and Nuclear Medicine Imperial College London

Comfort break
The use of MRI with disease modifying drugs for Alzheimer’s disease

Prof Frederik Barkhof, Consultant in Neuroradiology, University College London Queen Square Institute

Panel discussion: The novel therapies, imaging and how this could impact the NHS
Closing remarks

Dr George Petrides, Radiology Consultant, Newcastle Upon Tyne Hospitals

Close of meeting



Registrations will close at 1 hour before the webinar starts. Late registrations will not be accepted.

The agenda is subject to change at any time

If the event is recorded, we are only able to share presentations that we have received permission to share. There is no guarantee that all sessions will be available after the event, this is at the presenter’s and RSM’s discretion.

All views expressed at this event are of the speakers themselves and not of the Royal Society of Medicine, nor the speaker's organisations.

This event will be recorded and stored by the Royal Society of Medicine and may be distributed in future on various internet channels.